4-(4-(pyrrolidin-1-yl)phenyl)morpholine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 4-(4-(pyrrolidin-1-yl)phenyl)morpholine
• 英文别名: 4-(4-Pyrrolidin-1-ylphenyl)morpholine
• 化学式: C₁₄H₂₀N₂O
• 分子量: 232.326
• InChiKey: SVGMYHDWSLYZRZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  15.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-(4-硝基苯基)吗啉 在 palladium on activated charcoal 氢气 、 potassium carbonate 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 4-(4-(pyrrolidin-1-yl)phenyl)morpholine
  参考文献：
  名称：

  Preparation and Properties of N,N,N',N'-Tetrasubstituted 1,4-Benzenediamines.

  摘要：

  The synthesis of nine different N,N,N',N'-tetrasubstituted 1,4-benzenediamines is described. These compounds are of interest as mediators for glucose oxidase based biosensors and as donor molecules for conducting molecular solids. The electrochemical behaviour and the electronic absorption spectra have been investigated.

  DOI：

  10.3891/acta.chem.scand.50-1013

文献信息

• Palladium-Catalyzed Amination of Aryl Sulfides with Aliphatic Amines
  作者：Ke Gao、Hideki Yorimitsu、Atsuhiro Osuka

  DOI：10.1002/ejoc.201500226

  日期：2015.4

  Conditions for the palladium–NHC-catalyzed amination of aryl sulfides with aliphatic as well as aromatic amines were established. The KHMDS-mediated amination of heteroaryl sulfides could proceed without palladium. Based on the distinct difference in reactivity of C–Br and C–S bonds, a sequential amination of bromothioanisole can take place to install two different alkylamino groups onto the aromatic

  建立了钯-NHC 催化芳基硫化物与脂肪族和芳香族胺胺化的条件。KHMDS 介导的杂芳基硫化物胺化可以在没有钯的情况下进行。基于 C-Br 和 C-S 键反应性的明显差异，可以发生溴苯甲醚的顺序胺化，将两个不同的烷基氨基安装在一个锅中的芳环上。
• Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases
  申请人：Li Yun-Long

  公开号：US20050113344A1

  公开（公告）日：2005-05-26

  The present invention provides compounds of the formula I: its enantiomers, diastereomers, racemic mixtures thereof, prodrugs, crystalline forms, non-crystalline forms, amorphous forms thereof, solvates thereof, metabolites thereof, and pharmaceutically acceptable salts, wherein the ring A substituent groups are fully defined in the following disclosure. The compounds of formula I are inhibitors of metalloproteases such as matrix metalloproteases and sheddases, and are useful in treating diseases such as rheumatoid arthritis, psoriasis, neoplastic diseases, allergies and all those diseases wherein inhibition of MMPs is desirable.

  本发明提供了I式化合物：其对映体、非对映异构体、混合物、前药、晶体形态、非晶体形态、无定形形态、溶剂化物、代谢物和药学上可接受的盐，其中环A的取代基在以下披露中被充分定义。I式化合物是金属蛋白酶抑制剂，例如基质金属蛋白酶和脱落素酶，并且在治疗类风湿性关节炎、牛皮癣、肿瘤性疾病、过敏和所有需要抑制MMPs的疾病中有用。
• Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases
  申请人：Li Yun Long

  公开号：US20080167288A1

  公开（公告）日：2008-07-10

  The present invention provides compounds of the formula: its enantiomers, diastereomers, racemic mixtures thereof, prodrugs, crystalline forms, non-crystalline forms, amorphous forms thereof, solvates thereof, metabolites thereof, and pharmaceutically acceptable salts, wherein the ring A substituent groups are fully defined in the following disclosure. The compounds of formula are inhibitors of metalloproteases such as matrix metalloproteases and sheddases, and are useful in treating diseases such as rheumatoid arthritis, psoriasis, neoplastic diseases, allergies and all those diseases wherein inhibition of MMPs is desirable.

  本发明提供了公式的化合物：其对映异构体、非对映异构体、混合物、前药、晶体形式、非晶体形式、无定形形式、溶剂化物、代谢物和药学上可接受的盐，其中环A的取代基在下面的披露中被完全定义。公式化合物是金属蛋白酶抑制剂，如基质金属蛋白酶和脱落酶，可用于治疗风湿性关节炎、银屑病、肿瘤性疾病、过敏和所有需要抑制MMP的疾病。
• SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES
  申请人：Li Yun-Long

  公开号：US20110224189A1

  公开（公告）日：2011-09-15

  The present invention provides compounds of the formula: its enantiomers, diastereomers, racemic mixtures thereof, prodrugs, crystalline forms, non-crystalline forms, amorphous forms thereof, solvates thereof, metabolites thereof, and pharmaceutically acceptable salts, wherein the ring A substituent groups are fully defined in the following disclosure. The compounds of formula are inhibitors of metalloproteases such as matrix metalloproteases and sheddases, and are useful in treating diseases such as rheumatoid arthritis, psoriasis, neoplastic diseases, allergies and all those diseases wherein inhibition of MMPs is desirable.

  本发明提供了化合物的公式：其对映异构体，对映体混合物，前药，晶体形式，非晶体形式，无定形形式，其溶剂化物，代谢产物以及药学上可接受的盐，其中环A的取代基在以下披露中完全定义。公式化合物是金属蛋白酶抑制剂，例如基质金属蛋白酶和剪切酶，并且在治疗风湿性关节炎，牛皮癣，肿瘤性疾病，过敏和所有需要抑制MMP的疾病中有用。
• US7491724B2
  申请人：——

  公开号：US7491724B2

  公开（公告）日：2009-02-17